Exercise program for breast cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial involves a 24-week exercise program designed for patients with early-stage and locally advanced breast cancer who have undergone curative surgery and completed chemotherapy or radiotherapy. The program includes aerobic exercise and muscle strength training, with the first nine sessions supervised in person by physiotherapists, followed by remote monitoring or supervision at local gyms. The study aims to assess the impact of this exercise intervention on cardiorespiratory fitness, muscle strength, and quality of life among participants. Blood samples and questionnaires will be collected periodically to evaluate health outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with histologically or cytologically proven stage 1, 2, or 3 breast cancer
* Patients who have undergone curative breast surgery
* Patients who have received (neo)adjuvant chemotherapy (if given) and/or radiotherapy (if given)
* Females aged 21 years and older
* ≤ 8 weeks from breast surgery, or the last adjuvant chemotherapy or radiotherapy session, whichever is latest.

Exclusion Criteria:

* Cardiovascular, respiratory, musculoskeletal problems that preclude moderate physical activity.
* Major medical problems that are deemed by the investigator to be unsuitable for enrollment.

Where it's running

• National University Hospital
  Singapore, Singapore Recruiting
• National Cancer Centre
  Singapore, Singapore Recruiting
• Singapore General Hospital
  Singapore, Singapore Recruiting

Study contacts

• Principal investigator: Dr Elaine LIM, MD, PhD — National Cancer Centre, Singapore
• Study coordinator: Dr Elaine LIM, MD, PhD
• Email: elaine.lim.hsuen@singhealth.com.sg
• Phone: +65 64368000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Precision neoadjuvant therapy for operable breast cancer

  This study is testing if a personalized treatment approach using new drugs for operable breast cancer can work better than standard chemotherapy alone.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT05582499

• Personalized treatment for breast cancer using new drug agents

  This study is testing new drug combinations with standard chemotherapy to see which treatments work best for different types of breast cancer based on the specific characteristics of each patient's tumor.

  Recruiting at 32 sites Phase 2 QuantumLeap Healthcare Collaborative · Birmingham, Alabama and 41 other locations · NCT01042379

• PRT13722 in advanced HR+/HER2- breast cancer

  This early study tests PRT13722, by itself and with standard therapies, to see if it is safe and has any signs of activity in adults with HR+/HER2- breast cancer who have progressed on prior treatments.

  Recruiting Phase 1 Prelude Therapeutics Incorporated · Maumee, Ohio · NCT07905001

• One-week versus three-week partial breast irradiation for early-stage breast cancer

  This trial tests whether a shorter one-week partial breast irradiation plan is not worse than a three-week plan for women after breast-conserving surgery.

  Recruiting Fudan University · Shanghai · NCT07832279

• Culmerciclib with endocrine therapy before surgery for early HER2-negative hormone receptor-positive breast cancer

  This trial tests whether adding culmerciclib to an aromatase inhibitor before surgery helps women with certain early breast cancers better shrink tumors than an aromatase inhibitor alone.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07796880

• Partial Breast Radiation After Breast-Conserving Surgery Without Sentinel Node Biopsy

  This pilot study tests whether partial breast irradiation is safe for women who had breast-conserving surgery without sentinel lymph node biopsy or axillary dissection.

  Recruiting NYU Langone Health · New York, New York · NCT07723209

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.